Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Miracle Friends Evaluation

that was founded with a mission to address relational poverty and loneliness among PEH through the Miracle Friends (MF) program that matches unhoused individuals with housed volunteers who participate

Accepts healthy volunteers
  • 0 views
  • 10 Jul, 2022
  • 1 location
Impact of Hyperoxia and Involvement of the Immune System in Diving Accident (OXYDIVE)

The impact of oxygen therapy in many pathologies has been subject of recent work, arguing both favourable and harmful effects. Consequently, one can wonder about the influence of hyperoxic gas mixture during diving on the genesis of decompression sickness, but also about the systematic application of normobaric and hyperbaric oxygen …

Accepts healthy volunteers
  • 0 views
  • 01 May, 2022
  • 1 location
Efficacy of 1% Metformin Gel Mixed With PRF in Augmenting Narrow Ridge (MF)

This study aimed to evaluate the efficacy of 1% metformin gel mixed with PRF, in horizontal ridge augmentation with the split-crest technique, for implant placement.

Accepts healthy volunteers
  • 0 views
  • 28 Jun, 2022
  • 1 location
Mindfulness, Mental Fatigue, Inhibitory Control and Endurance Performance in Athletes

This study investigated the mediating effect of dispositional mindfulness on the impact of mental fatigue on neurocognitive functions and endurance performance in athletes.

Accepts healthy volunteers
  • 0 views
  • 04 Oct, 2022
  • 1 location
Itacitinib in Advanced Hepatocellular Carcinoma (JAKaL)

This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the …

  • 0 views
  • 04 Oct, 2022
  • 1 location
Integrated Exercise Approach Strength Postural Stability Menstrual Cycle Biomarkers Eumenorrheic Females

The study will determine the effects of integrated exercise approach on strength, postural stability and biomarkers (estrogen, progesterone and testosterone) of menstrual cycle in eumenorrheic females and translation of Unified Balance Scale will be done.

Accepts healthy volunteers
  • 0 views
  • 04 Oct, 2022
  • 1 location
The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa

This clinical trial aims to study the efficacy of umbilical cord-derived mesenchymal stem cells and their exosomes in the treatment of retinitis pigmentosa. The participants will be randomized into 3 groups. Functional and structural parameters will be compared before and after the injections and also will be compared among the …

corrected visual acuity
electroretinogram
genetic analysis
  • 0 views
  • 07 Oct, 2022
  • 1 location
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of

  • 1 views
  • 30 May, 2022
  • 38 locations
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

  • 4 views
  • 26 May, 2022
  • 37 locations
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor

  • 169 views
  • 04 Oct, 2022
  • 133 locations